Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Seres

- PMLiVE

AstraZeneca announces $2.5bn investment in China to boost R&D capabilities

The funds will go towards a new global research and development centre in Beijing’s BioPark

- PMLiVE

AstraZeneca to expand cell therapy capabilities with $1bn EsoBiotec acquisition

The biotech’s ENaBL platform enables cell therapies to be administered through an IV injection

- PMLiVE

AZ to seek approval for “long-acting” COVID-19 antibodies

AZD7442 significantly reduced the risk of developing symptomatic COVID-19 in phase 3 trial and is a one-dose treatment that can be given via an intramuscular injection

AstraZeneca AZ

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year

AstraZeneca AZ

AZ signs $20m deal with Seres for microbiome project

Shares in Seres shot up 25% after the deal was announced

- PMLiVE

AZ says Brilinta hits the mark in diabetic heart disease

The drug can reduce cardiovascular events in diabetics with CAD

- PMLiVE

Cutting through the noise: CRISPR

AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery

- PMLiVE

AZ says dropping MedImmune will help ‘streamline’ its R&D

Will also drop other candidates that haven’t hit the mark

AstraZeneca AZ

US, EU regulators back rapid reviews of AZ’s RSV med

Positive top-line data triggered speedy assessments

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

Q&A: Pernille Laerkegaard Hansen

Gemma Jones interviews AstraZeneca's Senior Research Director, Head of Bioscience

- PMLiVE

China approves Ironwood Pharma’s IBS treatment

Coincides with AZ's Mark Mallon taking over as CEO

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links